Ram Salvaraju

“I don't know what the technical difficulty was. So just very quickly, I wanted to know if you could provide us with some additional sense of what other directions you might pursue with future clinical investigation of the applicability of certain elements of your product range.”

“Firstly, I was wondering if you could provide us with any update on the lawsuit filed against the FDA and when you anticipate any potential further progress on that front and the possibility of some decision in that proceeding.”

“I was wondering if you could provide us with some additional granularity regarding how you expect sales and promotional strategies to shift over the course of the remainder of 2026, just based on trends that you're seeing in the market and product lines, products, product initiatives that you expect are likely to be…”

“I was wondering if you could provide us with some additional granularity regarding how you expect sales and promotional strategies to shift over the course of the remainder of 2026, just based on trends that you're seeing in the market and product lines, product initiatives that you expect are likely to be most…”

“Hello, everyone, and welcome to this latest in a series of fireside chats here at the H.C. Wainwright Neuroperspectives Conference. My name is Ram Salvaraju, and I'm a Managing Director and Senior Healthcare Equity Research Analyst in Wainwright's Equity Research Department.”